Prestige Consumer Healthcare Inc. (PBH) Cash Flow Statement
Where PBH’s cash came from and went, FY2026
March 31, 2026 · U.S. dollars- Cash from operations
- $257.6M +2.4% vs FY2025
- Capital expenditures
- $11.2M 1.0% of revenue
- Free cash flow
- $246.4M 22.6% margin
- Returned to shareholders
- $156.3M 63% of free cash flow
- Change in cash
- −$34.0M cash at year-end $63.9M
Drawn to scale: where the cash came from and how it was used. Hover for values.
PBH operating cash flow, capex and free cash flow
PBH cash flow trends, FY2017–FY2026
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Operating cash flow | $147.8MFY2017 | $257.6MFY2026 | +6.4%/yr | |
| Capital expenditures | $3.0MFY2017 | $11.2MFY2026 | +15.8%/yr | |
| Free cash flow | $144.8MFY2017 | $246.4MFY2026 | +6.1%/yr | |
| Free cash flow margin | 16.4%FY2017 | 22.6%FY2026 | +6.2 pts | |
| Operating cash flow / net income | 2.13FY2017 | 1.35FY2026 | −0.78 | |
| Stock-based compensation | $8.1MFY2017 | $10.8MFY2026 | +3.2%/yr | |
| Dividends paid | $0FY2017 | $4.1MFY2022 | — | |
| Share buybacks (net) | $1.4MFY2017 | $156.3MFY2026 | +68.5%/yr | |
| Capex / revenue | 0.3%FY2017 | 1.0%FY2026 | +0.7 pts |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
PBH cash flow by activity
PBH net income vs operating cash flow
Operating cash flow above net income usually means earnings are backed by cash (depreciation and stock-based pay are non-cash expenses).
PBH cash flow statement
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||
| Net income | $190.3M | $214.6M | $209.3M | −$82.3M | $205.4M | $164.7M | $142.3M | −$35.8M | $339.6M | $69.4M |
| Depreciation & amortization | $31.3M | $30.2M | $30.7M | $32.6M | $32.1M | $30.2M | $29.0M | $31.8M | $33.4M | $25.8M |
| Stock-based compensation | $10.8M | $11.2M | $14.0M | $12.4M | $9.0M | $8.5M | $7.6M | $7.4M | $8.9M | $8.1M |
| Change in working capital | −$17.6M | −$41.9M | −$39.8M | −$53.9M | −$10.9M | −$5.6M | $8.8M | −$8.3M | −$15.8M | −$13.3M |
| Other non-cash items | $42.8M | $37.5M | $34.7M | $320.8M | $24.4M | $37.8M | $29.4M | $194.2M | −$156.0M | $57.8M |
| Cash from operating activities | $257.6M | $251.5M | $248.9M | $229.7M | $259.9M | $235.6M | $217.1M | $189.3M | $210.1M | $147.8M |
| Investing activities | ||||||||||
| Capital expenditures | −$11.2M | −$8.2M | −$9.6M | −$7.8M | −$9.6M | −$22.2M | −$14.6M | −$10.5M | −$12.5M | −$3.0M |
| Investments (net) | — | −$17.5M | −$20.1M | −$11.6M | −$256.5M | −$22.2M | −$16.6M | $55.4M | −$11.6M | −$694.6M |
| Acquisitions & other investing | −$125.7M | $8.2M | $9.6M | $7.8M | $9.6M | $22.2M | $14.6M | $10.5M | $12.5M | $3.0M |
| Cash from investing activities | −$136.8M | −$17.5M | −$20.1M | −$11.6M | −$256.5M | −$22.2M | −$16.6M | $55.4M | −$11.6M | −$694.6M |
| Financing activities | ||||||||||
| Dividends paid | — | — | — | — | −$4.1M | −$2.9M | −$1.3M | −$2.9M | $0 | $0 |
| Share repurchases & issuance (net) | −$156.3M | −$51.5M | −$25.0M | −$50.0M | −$2.9M | −$11.9M | −$56.7M | −$50.0M | −$1.1M | −$1.4M |
| Net borrowing (repayment) | $504,000 | −$139.5M | −$227.8M | −$135.0M | −$9.1M | −$267.7M | −$74.6M | −$200.0M | −$209.5M | $1.43B |
| Shares issued | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other financing | −$283,000 | $9.0M | $11.8M | −$846,000 | $8.6M | $3.0M | $1.2M | $3.6M | $1.6M | −$863.7M |
| Cash from financing activities | −$156.1M | −$182.1M | −$241.0M | −$185.8M | −$7.6M | −$279.4M | −$131.4M | −$249.3M | −$209.0M | $561.9M |
| Summary | ||||||||||
| Net change in cash | −$34.0M | $51.4M | −$12.0M | $31.3M | −$5.1M | −$62.5M | $67.2M | −$5.0M | −$9.3M | $14.6M |
| Cash at end of period | $63.9M | $97.9M | $46.5M | $58.5M | $27.2M | $32.3M | $94.8M | $27.5M | $32.5M | $41.9M |
| Free cash flow | $246.4M | $243.3M | $239.4M | $221.9M | $250.3M | $213.4M | $202.6M | $178.8M | $197.6M | $144.8M |
| Free cash flow margin | 22.6% | 21.4% | 21.3% | 19.7% | 23.0% | 22.6% | 21.0% | 18.3% | 19.0% | 16.4% |
| Capex / revenue | 1.0% | 0.7% | 0.8% | 0.7% | 0.9% | 2.4% | 1.5% | 1.1% | 1.2% | 0.3% |
| Operating cash flow / net income | 1.35 | 1.17 | 1.19 | — | 1.27 | 1.43 | 1.53 | — | 0.62 | 2.13 |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||||
| Net income | $29.2M | $53.9M | $46.7M | $42.2M | $47.5M | $50.1M | $61.0M | $54.4M | $49.1M | $49.5M | $53.0M | $53.6M |
| Depreciation & amortization | $8.8M | $8.4M | $7.6M | $7.7M | $7.7M | $7.3M | $6.9M | $7.9M | $8.1M | $7.8M | $7.6M | $7.6M |
| Stock-based compensation | $4.0M | $2.6M | $2.7M | $1.8M | $3.7M | $2.7M | $2.9M | $2.1M | $3.4M | $3.7M | $2.4M | $3.7M |
| Change in working capital | $23.1M | −$20.5M | $4.9M | −$14.0M | $12.0M | −$21.8M | −$10.9M | −$622,000 | −$8.6M | −$5.5M | $18,000 | −$11.0M |
| Other non-cash items | $5.8M | −$1.6M | $16.3M | $19.9M | $8.2M | $23.5M | $5.2M | $6.0M | $2.8M | $11.4M | $8.3M | $8.5M |
| Cash from operating activities | $70.8M | $42.8M | $78.3M | $57.5M | $79.0M | $61.8M | $65.1M | $69.8M | $54.8M | $66.9M | $71.5M | $62.5M |
| Investing activities | ||||||||||||
| Capital expenditures | −$3.7M | −$5.2M | −$3.0M | −$2.1M | −$838,000 | −$3.5M | −$1.6M | −$2.0M | −$1.2M | −$3.1M | −$2.0M | −$2.9M |
| Investments (net) | — | — | — | −$2.9M | −$1.9M | −$3.5M | −$9.8M | −$2.0M | −$2.1M | −$15.0M | −$4.5M | −$2.9M |
| Acquisitions & other investing | −$1.06B | $1.8M | −$125.5M | $2.1M | $838,000 | $3.5M | $1.6M | $2.0M | $1.2M | $3.1M | $2.0M | $2.9M |
| Cash from investing activities | −$1.06B | −$3.4M | −$128.6M | −$2.9M | −$1.9M | −$3.5M | −$9.8M | −$2.0M | −$2.1M | −$15.0M | −$4.5M | −$2.9M |
| Financing activities | ||||||||||||
| Share repurchases & issuance (net) | −$2.7M | −$690,000 | −$45.8M | −$75.0M | −$34.8M | −$11.3M | −$2.4M | −$11.8M | −$26.0M | $0 | $0 | −$15.8M |
| Net borrowing (repayment) | $1.05B | −$37.7M | $39.4M | −$539,000 | −$608,000 | −$2.6M | −$60.2M | −$41.0M | — | — | — | −$55.7M |
| Shares issued | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other financing | −$24.0M | $316,000 | −$290,000 | $590,000 | −$899,000 | $2.5M | $8.7M | $1.6M | −$39.5M | −$68.4M | −$64.8M | $18.0M |
| Cash from financing activities | $1.02B | −$38.1M | −$6.7M | −$74.9M | −$36.3M | −$11.5M | −$53.9M | −$51.2M | −$65.5M | −$68.4M | −$64.8M | −$53.5M |
| Summary | ||||||||||||
| Net change in cash | $25.3M | $1.5M | −$56.7M | −$20.4M | $41.6M | $47.0M | −$666,000 | $17.3M | −$12.2M | −$17.1M | $3.5M | $5.5M |
| Cash at end of period | $89.1M | $63.9M | $62.4M | $119.1M | $139.5M | $97.9M | $50.9M | $51.5M | $34.3M | $46.5M | $63.6M | $60.1M |
| Free cash flow | $67.1M | $37.6M | $75.3M | $55.4M | $78.2M | $58.4M | $63.5M | $67.8M | $53.6M | $63.8M | $69.5M | $59.5M |
| Free cash flow margin | 25.2% | 13.4% | 26.6% | 20.2% | 31.3% | 19.7% | 21.9% | 23.9% | 20.1% | 23.0% | 24.6% | 20.8% |
| Capex / revenue | 1.4% | 1.9% | 1.1% | 0.8% | 0.3% | 1.2% | 0.5% | 0.7% | 0.4% | 1.1% | 0.7% | 1.0% |
| Operating cash flow / net income | 2.43 | 0.79 | 1.68 | 1.36 | 1.66 | 1.23 | 1.07 | 1.28 | 1.12 | 1.35 | 1.35 | 1.17 |
Negative numbers are cash paid out. Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported; data from EODHD.
PBH cash generation
In fiscal 2026 (ended March 31, 2026), Prestige Consumer Healthcare generated $257.6 million of cash from operations (up 2.4%) and spent $11.2 million on capital expenditures, leaving free cash flow of $246.4 million, 22.6% of revenue. It returned $156.3 million to shareholders through dividends ($0) and net share buybacks ($156.3 million). Cash and equivalents fell by $34.0 million over the year.
Related: PBH income statement, PBH balance sheet. See the PBH stock overview for the latest quote and news.
PBH cash flow FAQ
What is Prestige Consumer Healthcare's free cash flow?
Prestige Consumer Healthcare's free cash flow was $246.4 million in fiscal 2026: $257.6 million of operating cash flow minus $11.2 million of capital expenditures It was $243.3 million a year earlier..
How much cash does Prestige Consumer Healthcare generate from operations?
Prestige Consumer Healthcare generated $257.6 million of cash from operating activities in fiscal 2026, 1.35 times its net income of $190.3 million.
How much does Prestige Consumer Healthcare spend on capital expenditures?
Prestige Consumer Healthcare spent $11.2 million on capital expenditures in fiscal 2026, 1.0% of revenue, compared with $8.2 million the year before.
How much stock does Prestige Consumer Healthcare buy back?
Prestige Consumer Healthcare spent $156.3 million on net share repurchases in fiscal 2026.